Osteogenesis imperfecta type 3

Osteogenesis imperfecta type 3 (OI type III), also known as the progressively deforming type of osteogenesis imperfecta or severe non-lethal OI, is a rare genetic connective tissue disorder characterized by extreme bone fragility and progressive skeletal deformities. It is the most severe form of osteogenesis imperfecta compatible with survival beyond the neonatal period. The condition is caused primarily by mutations in the COL1A1 or COL1A2 genes, which encode the alpha chains of type I collagen — a critical structural protein found in bones, skin, tendons, and other connective tissues. In some cases, autosomal recessive forms have been identified involving genes such as CRTAP, LEPRE1 (P3H1), and PPIB, which are involved in collagen processing. Individuals with OI type III typically experience numerous fractures beginning at birth or in utero, leading to progressive long bone deformities and severe short stature. The skeleton is markedly affected, with bowing of the limbs, scoliosis, and vertebral compression fractures being common. Craniofacial features may include a triangular face, relative macrocephaly, and dentinogenesis imperfecta (discolored, translucent, and fragile teeth). Blue or gray sclerae may be present in infancy but often lighten with age. Hearing loss can develop in adolescence or adulthood. Respiratory complications due to chest wall deformity and scoliosis are a significant concern and can affect life expectancy. Joint hypermobility, easy bruising, and muscle weakness are also frequently observed. Management of OI type III is multidisciplinary and focuses on maximizing function and minimizing fractures and deformity. Bisphosphonate therapy (such as intravenous pamidronate or zoledronic acid) is widely used to increase bone mineral density and reduce fracture frequency, particularly in children. Orthopedic interventions, including intramedullary rodding of long bones, are commonly performed to correct deformities and provide internal support. Physical therapy and rehabilitation are essential to maintain mobility and muscle strength. Respiratory monitoring and management are important given the risk of restrictive lung disease. While there is no cure, ongoing research into gene therapy, cell-based therapies, and novel pharmacological agents offers hope for improved outcomes in the future.

Common questions about Osteogenesis imperfecta type 3